Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine Interaction Study
NCT06726382Phase 1Completed
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esketamine in major depressive disorder (MDD) (4 arms), sponsored by Helsinki University Hospital. Primary endpoint: Area under the plasma concentration-time curve of esketamine up to 24 hours. Started Dec 2024; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06726382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726382.